

Subject Index

- Acute myeloid leukemia, 54
- AICD, in systemic T cells in cancer,
 - gangliosides tumor secretion and, 75–78
- AIRE, transcription factor, 10–11
- All-*trans* retinoic acid, 159, 180
- Alpha7 nicotinic acetylcholine receptor (alpha7nAChR), 209
- AML, *see* Acute myeloid leukemia
- Androgens, 18–20
- Anti-CD25 antibody (7D4), 56–57
- Antigen-presenting cells, 10–12, 15, 17, 31, 48, 89, 137, 139, 159, 197
 - MDSC differentiation in, 180–181
 - signaling pathways in, T-cell activation vs. tolerance and
 - SOCS, 210–212
 - STAT3, 205–210
 - tyrosine kinase receptors, 201–205
 - and tolerance to tumor antigens, 198–200
- Antigen recognized by Treg cells 1, 55
- Anti-HA CD4⁺ T cells, 51
- Antitumor T cells, cancer-induced signaling
 - defects in, 69
 - AICD in systemic T cells, enhanced sensitivity to, 75–78
 - cAMP-dependent modulation of proximal TCR signal transduction, Csk activity and, 86–90
 - defective proliferation, 74–75
 - function, systemic defects in, 71–74
 - p56^{lck} activity regulation, 83–86
 - signal transduction, in cytolytic T cells, 80–82
 - soluble reactive oxygen and nitrogen metabolites and, 78
 - TIL signal transduction inhibition by tumor, 78–80
- APCs, *see* Antigen-presenting cells
- Arginase (ARG), 160
 - ARG I/II, 221
 - arginine and cancer, 222–224
 - dependent suppression, 174
 - MDSC and production of, 224–226
- L-Arginine
 - arginase and cancer, 222–224
 - metabolism, 174–175
 - metabolism, in M1 and M2 macrophages, 142–143
 - T-cell function and, 221–222
- β-Arrestin, 86
- ARTC1, *see* Antigen recognized by Treg cells 1
- L-Ascorbic acid, 262
- ATRA, *see* All-*trans* retinoic acid
- B and T-lymphocyte attenuator, 30
- B-cell lymphomas, 9, 12
- Bcl-2 protein expression, 241
- B16F10, melanoma cell line, 44
- B7 homolog 1 (B7-H1)
 - mediated suppression
 - CTL lysis, resistance to, 35
 - T-cell anergy and exhaustion, generation and maintenance, 35–37
 - T-cell deletion/apoptosis, 33–35
 - upregulation in cancer, chronic viral infections and, 32–33
- B7-H1-PD-1 pathway, 32, 37
- B7 ligand family, 31
- B16 melanoma model, 57
- 5-Bromo-2'-deoxyuridine (BrdU), 51
- BTLA, *see* B and T-lymphocyte attenuator
- Cancer
 - arginine, arginase and, 222–224
 - B7-H1 upregulation in, chronic viral infections and, 32–33

- Cancer (cont.)
 dysfunctional immune response in, 219–221
 immune-suppressive mechanisms and, 1
 characteristics of, 3
 chemotherapy and, 4
 specific vs. non-specific, 2–3
 strategies for, 3–4
 immunobiology of dendritic cells in, *see* Dendritic cells
 induced signaling defects, in antitumor T cells, 69
 AICD in systemic T cells, enhanced sensitivity to, 75–78
 cAMP-dependent modulation of proximal TCR signal transduction, Csk activity and, 86–90
 defective proliferation, 74–75
 function, systemic defects in, 71–74
 p56^{lck} activity regulation, 83–86
 signal transduction, in cytolytic T cells, 80–82
 soluble reactive oxygen and nitrogen metabolites and, 78
 TIL signal transduction inhibition by tumor, 78–80
 MDSC in, *see* Myeloid-derived suppressor cells
 ROC in T-cell defects in, *see* Reactive oxygen species
 Treg in, 41
 expansion in tumor bearers, mechanism, 50–54
 functional inactivation, 58–59
 in human cancer, 45–46
 in murine tumors, 43–45
 neutralization, by depletion, 56–58
 suppression in anti-tumor immunity, targets of, 46–50
 tumor-associated, antigen specificity of, 54–55
 Carbohydrate-recognition domain, 235, 244
 Catalase, 262
 Cationic amino acid transport system (CAT), 224–225
 Cbp, *see* Csk binding protein
 CCAAT/enhancer-binding protein β , 224
 CCL22, macrophage-derived chemokine, 51, 140
 CCL17, thymus- and activation-regulated chemokine, 140
 CCR4 receptor, 51
 CD11b⁺/Gr1⁺ cells, 158–160, 175
 Cdc42 and Rac1 genes, 114
 CD4⁺CD25⁻ T cells, 53–54
 CD4⁺ CD25⁺ Treg homeostasis, regulation, 176–178
 CD4 cells, 9, 11–13, 19
 CD11c^{int} myeloid DC, 118
 CD8⁺ cytolytic T-cell, 33–34, 47, 49, 106, 157, 282, 284
 signal transduction in, 80–82
 CD23, Fc receptor for IgE, 139
 CD163, hemoglobin scavenger receptor, 139
 CD22, inhibitory signaling receptor, 84
 CD28-like receptors, 30–31
 CD4⁺ T-cells, 41, 49, 56, 133, 141, 198
 CD8⁺ T cells, 9–10, 15, 79, 108, 133, 158, 173, 179
 “Cellular (phagocytic) theory of immunity,” 131
 CGD, *see* Chronic granulomatous disease
 Chemotherapy, 4
 CHO cells, 236
 CHOP gene, 224
 Chronic granulomatous disease, 263
 Chronic myelogenous leukemia, 203
c-kit and imatinib mesylate, 203–205
 “Classically activated” (M1) and “alternatively activated” (M2) macrophages, 138–141
 arginine metabolism in, 142–143
 and M1 and M2 paradigm, 141–142
 M1/M2 nomenclature, 144–145
 transcriptional signatures of, 143–144
 CML, *see* Chronic myelogenous leukemia
 Colony stimulating factor-1, 135, 163
 Complete Freund Adjuvant (CFA), 199
 Core-2- β -1,6-*N*-acetylglucosaminyltransferase (C2GnT), 240
 COS-7 L cells, 224
 COX-2, *see* Cyclooxygenase-2
 CRD, *see* Carbohydrate-recognition domain
 CSF-1, *see* Colony stimulating factor-1
 Csk activity, cAMP-dependent modulation of TCRs signal transduction and, 86–90
 Csk binding protein, 87
 CTL, *see* CD8⁺ cytolytic T-cell
 CTLA-4, *see* Cytotoxic T-lymphocyte antigen-4
 CXCL14 protein, 108–109
 Cyclooxygenase-2, 54, 111, 134, 169, 181
 Cyclophosphamide (Cytoxin), 17

- Cytokines, 53, 139
 galectin-3 and, 247
 proinflammatory and anti-inflammatory,
 galectin-1 and, 239
- Cytotoxic T-lymphocyte antigen-4, 30, 42, 44,
 48, 50, 58, 119
- DC, *see* Dendritic cells
- Dectin-1 (β -glucan receptor), 140
- Delayed-type hypersensitivity, 220
- Dendritic cells, 12, 32, 47, 51, 53, 76,
 158–159, 199
 immunobiology, in cancer, 101–102
 abnormalities of, 104–105
 alterations, 103–109
 dysfunction mechanisms, 109–114
 tumor escape mechanisms, 114–120
- Dinileukin difitox, CD25-depleting agent,
 46, 57
- DTH, *see* Delayed-type hypersensitivity
- EL-4 cells, 79
- Electromobility shift assay (EMSA), 206
- Env-specific T cells, 8
- Epidermal growth factor (EGF), 136
- EP2 receptor, 111
- Epstein–Barr virus proteins, 69
- Extracellular regulated kinase (ERK), 114
- Flavin adenine dinucleotide (FAD), 259, 263
- Foxp3 expression, 11, 42, 51, 53, 57
- β -Galactosides, 235
- Galectin-1, 76–77
 adaptive immune responses regulation and,
 237–241
 biochemistry and cell biology, 236
 cell adhesion, migration and angiogenesis
 and, 243
 monocytes, macrophages, dendritic cells
 and neutrophils, 242–243
 tumor-immune privilege, establishment and
 maintenance, 241–242
 in tumor microenvironment, 237
- Galectin-3
 biochemistry and cellular biology, 244–245
 expression, in tumors, 245
 immune cell activation modulation and,
 247–248
 T-cell responses regulation and, 245–247
 in tumor-immune escape, 249–250
- Ganglioside receptor, 76
- GAS6, *see* Growth arrest-specific protein 6
- Gastrointestinal sarcoma tumors, 203
- GCN2 kinase, 224
- GIST, *see* Gastrointestinal sarcoma tumors
- Glucocorticoid-induced tumor necrosis factor
 receptor (GITR), 42, 45, 51, 58
- Glutathione (GSH), 262
- Glutathione-S-transferase, 262
- Glycan-binding proteins, *see* Galectins
- GM-CSF, *see* Granulocyte macrophage-colony
 stimulating factor
- gp91phox, 263
- gp100 tumor antigen, 33
- Graft-*versus*-host disease, 32, 176
- Granulocyte macrophage-colony stimulating
 factor, 45, 59, 117, 159, 165–166,
 178, 225, 269
- Gr1⁺ cells, 158, 161, 173
- GRIFIN (galectin-*r* elated *i* nter *f* iber
 protein), 235
- Growth arrest-specific protein 6, 202
- GST, *see* Glutathione-S-transferase
- GVHD, *see* Graft-*versus*-host disease
- hCG, *see* Human chorionic gonadotropin
- Head and neck squamous cell carcinoma,
 106–108, 242
- Helicobacter pylori*, 36
- Hepatitis B/C virus (HBV/HCV), 33, 36
- Hepatocellular carcinoma, 106
- Her-2-expressing tumor, 50
- Herpes virus entry mediator, 30
- Her-2 receptor, 55
- HLA-DR expression, 118, 178
- HLA-DR⁺ immature cells (DR+IC), 107
- HNSCC, *see* Head and neck squamous cell
 carcinoma
- Hodgkin's disease (HD), 46, 220
- Human cancer, Treg in, 45–46
- Human chorionic gonadotropin, 112
- Human immunodeficiency virus (HIV),
 33, 36
- Human leukocyte antigen G (HLA-G), 112
- Human MDSCs, 178–179
- “Humoral” theory, of immunity, 131
- HVEM, *see* Herpes virus entry mediator
- Hydrogen peroxide (H₂O₂), 260
- 3-Hydroxyanthranilic acid, 115
- Hydroxyl radical (OH[•]), 260
- Hypochlorous acid (HOCl), 260–261
- Hypoxia-inducible factor (HIF) 1 α and
 2 α , 134
- IDO, *see* Indoleamine-2,3-dioxygenase
- IFN- γ , *see* Interferon- γ

- IgG-TGF- β complex, 173
 IL-2, *see* Interleukin-2
 IL-6, 164
 IL-10, 166, 202, 208
 IL-13, 167
 IL-10+CCR7+CD45RO+CD8+ regulatory T cells, 115
 IL-13/IL4R α /STAT6 pathway, 183–184
 IL-2 plus anti-CD3 ϵ -activated killer cells, 71
 ILT4, *see* Immunoglobulin-like transcript 4
 Immature myeloid dendritic cells (IMDC), 51, 53
 Immune suppression mechanisms, MDSCs and, 172
 indirect, CD4⁺ CD25⁺ Treg homeostasis regulation, 176–178
 L-arginine metabolism, 174–175
 reactive oxygen species (ROC), 175–176
 TGF- β , 173
 Immunoglobulin (Ig) superfamily, 30
 Immunoglobulin-like transcript 4, 112
 Immunoreceptor tyrosine-based activation motif, 30, 84
 Immunoreceptor tyrosine-based inhibition motif, 30, 32, 84–85
 Immunoreceptor tyrosinebased switch motif, 30, 32
 Indoleamine dioxygenase, 2
 Indoleamine-2,3-dioxygenase, 115, 163
 activation, 47–48
 macrophages and suppression of tumor immunity and, 146–147
 Inducible costimulator (ICOS), 30
 Inducible costimulator ligand (ICOS-L), 119–120
 Inducible nitric oxide synthase, 134, 140, 142
 “Infectious tolerance,” 52
 iNOS, *see* Inducible nitric oxide synthase
 α v β 3 Integrin, 167
 Interferon- γ , 139, 141, 167–169, 267
 Interleukin-2, 41, 47, 51, 57, 107
 Interleukin-3 (IL-3), 225
 ITAM, *see* Immunoreceptor tyrosine-based activation motif
 ITIM, *see* Immunoreceptor tyrosine-based inhibition motif
 ITSM, *see* Immunoreceptor tyrosinebased switch motif

 Janus activated kinase (JAK) family, 114, 170, 205, 210
 Janus kinase 2 (JAK2), 145, 171, 210
 Jurkat cells, 76–77, 246

 Kinase inhibitory region (KIR), 210
 Kynurenine pathway, 115

 LAGE1, 55
 Langerhans cells, 105
 Latency-associated protein (LAP), 47
 LCMV, *see* Lymphocytic choriomeningitis virus
Leishmania, 141
 Lewis lung carcinoma, 166, 181
 Lipopolysaccharide (LPS), 138–139
Listeria monocytogenes, 79
 LMB-2, fusion protein, 57
 Low molecular weight proteins (LMP)-2 and LMP-7, 167–168
 Lung squamous cell carcinoma, 111
 Ly49 molecules, 83
 Lymphocytic choriomeningitis virus, 33, 36

 Macrophage colony stimulating factor, 163, 200, 201
 Macrophage inhibitory factor, 136
 Macrophages, tumor development and, *see* Tumor-associated macrophages
 MAPK, *see* Mitogen-activated protein kinase
 Matrix metalloprotease-9, 136, 164
 MCA38 tumor cells, 72, 74, 79–80, 220
 MC57-gp33-Lo cancer cells, 285
 M-CSF, *see* Macrophage colony stimulating factor
 MC57-SIY-Lo tumors, 285
 M15, CTL clone, 33
 MDSC, *see* Myeloid-derived suppressor cells
 624mel, human melanoma cell line, 33
 MHC–peptide complex and TCRs, interaction, 29–30
 MIF, *see* Macrophage inhibitory factor
 Mitogen-activated protein kinase, 113–114, 266

 Mixed leukocyte reaction (MLR), 166
 M1/M2 nomenclature, 144–145
 MMP-9, *see* Matrix metalloprotease-9
 mTECs, *see* Thymic medullary epithelial cells
 MUC1 glycoprotein, 112
 Murine tumors, Treg in, 43–45
 Myeloid-derived suppressor cells, 48, 54, 78, 85, 142, 219, 267
 arginase production and, 224–226
 biology and function, 158–160
 dependent immune suppression, mechanism, 172–178
 differentiation in fully mature APCs, 180–182

- expansion, recruitment and activation
 regulation, tumor-derived factors
 and, 161–169
- functions, transcription factors regulating,
 170–172
- history and nomenclature, 157–158
- human, 178–179
- IL-13/IL4R α /STAT6 pathway, 183–184
- and ROS, 268–269
- suppressive pathways, pharmacological
 inhibition, 182–183
- TAMS and, 147–149
- and tumor progression, 160–161
- in vivo depletion of, 179–180
- β 1,6-*N*-acetylglucosaminyltransferase
 V, 247
- Naïve T cells, 52–56, 70, 101, 241
- Natural killer (NK) cells, 47–48, 133,
 139, 157
- Natural suppressor (NS) cells, 157–158
- NF- κ B, transcription factor, 138, 207, 265
- Nicotinamide adenine dinucleotide phosphate
 (NADPH) oxidase
 biological roles, 264–266
 components of, 263–264
- Nitric oxide synthase (NOS2), 160, 173,
 221, 223
 and T-Cell Function, 226–227
- Non-CD8⁺ T cells, 72
- Non-Hodgkin lymphoma, 46
- Nonobese diabetic (NOD) mice, 36
- Norepinephrine, 103
- Nor-NOHA, arginase inhibitor, 225
- North's suppressor T cells, 44
- NOS-dependent suppression, 174–175
- NOX2, *see* gp91phox
- Ontak, *see* Dinileukin difitox
- OT-1 cells, 36
- Ovalbumin (OVA), 176
- OX40, 59
- Pathogen-associated molecular patterns
 (PAMPs), 12
- PBL T cells, 76
- PC61 antibody, 50
- PD-1, B7 receptor family member,
 32, 36
- Peripheral blood mononuclear cells
 (PBMC), 248
- Peroxynitrite (ONOO⁻), 261, 270–272
- PGEs, *see* Prostaglandins
- Phosphodiesterases (PDE), 88–89
- Phosphoinositide 3-kinase (PI3K), 114
 inhibitors, 202
- PI3K/AKT pathway, 202
- Plasmacytoid DC (pDC), 115,
 117–119
- p56^{lck} activity, 79, 81, 82, 87
 regulation, by inhibitory phosphatases,
 83–86
- p38 MAPK, 114
- Pmel-17/gp100, 8
- p47phox, 263–264
- Program death 1 (PD-1), 30
- Programmed death-ligand 2 (B7-DC; CD273),
 109, 166
- Prostaglandins, 111–112, 169
- Prostate-specific antigen (PSA), 112
- Protein tyrosine phosphatases (PTPs), 266
- P815 tumor model, 33–34
- Rac proteins, 264
- RCC, *see* Renal cell carcinoma
- Reactive nitrogen intermediates, 175
- Reactive oxygen species, 175–176
 T-cell defects in cancer and, 259
 cellular defenses, 262
 myeloid cell-mediated immune
 suppression in cancer and,
 266–274
 NADPH, as source in myeloid cells,
 263–264
 NADPH oxidase, biological roles,
 265–266
 types and biological function, 260–261
- Regulatory T cells, in cancer, 41, 115
 expansion in tumor bearers, mechanism,
 50–54
 functional inactivation, 58–59
 in human cancer, 45–46
 in murine tumors, 43–45
 neutralization, by depletion, 56–58
 suppression in anti-tumor immunity, targets
 of, 46–50
 tumor-associated, antigen specificity of,
 54–55
- RELB1 proteins, 207
- Renal cell carcinoma, 33, 226
- RNI, *see* Reactive nitrogen intermediates
- ROC, *see* Reactive oxygen species
- Shp-1 binding domain (SH2), 83, 85, 87
- Shp-1, nonmembrane protein tyrosine
 phosphatase, 83–86

- Signal transducer and activator of transcription (STAT) family, 113
- STAT1, 170–171, 208
- STAT3, 171–172, 205–210
- activation, 112–113
- inhibition, 181–182
- STAT6, 145–146, 172
- Singlet oxygen, 260
- Smad signaling pathway, 113
- S100 proteins, 264
- Src homology 2-containing inositol-5' phosphatase (SHIP), 146
- STAT1, 170–171, 208
- STAT3, 171–172, 205–210
- activation, 112–113
- inhibition, 181–182
- STAT6, 145–146, 172
- ST6Gal-I sialyltransferase, 240
- Superoxide dismutases (SOD), 260, 262
- Suppressors of cytokine signaling 1/3 (SOCS1/3), 210–213
- Systemic lupus erythematosus (SLE), 211–212
- TAMs, *see* Tumor-associated macrophages
- T-cell
- adhesion
- and extravasation, galectin-1 in, 239–240
- and migration, galectin-3 and, 247
- energy and exhaustion, generation and maintenance, 35–37
- co-signaling pathways, 29–31
- deletion/apoptosis, 33–35
- function
- arginine and, 221–222
- nitric oxide synthase (NOS2) and, 226–227
- tolerance mechanisms, tumor-associated, 7
- Env-specific T cells, 8
- hormones and tumor immunity and, 18–21
- peripheral self-antigen- and tumor-associated antigen-induced, 10–18
- tumor-HA vs self-HA, tolerance, 12
- See also Specific types*
- T-cell receptors (TCRs), 9, 13, 54–55, 73, 226
- MHC– peptide complex, interaction, 29–30, 81
- signaling complex, 72, 77, 80
- signal transduction
- cAMP-dependent modulation of, Csk activity and, 86–90
- galectin-1 and, 237
- TCR $\alpha\beta$, antigen receptor, 80
- TDFs, *see* Tumor-derived factors
- TEMs, *see* Tie2-expressing monocytes
- Th17 cells, 53
- T-helper lymphocytes, 49
- Thymic medullary epithelial cells, 10–11
- Tie2-expressing monocytes, 161
- TIL, *see* Tumor-infiltrating lymphocytes
- TKRs, *see* Tyrosine kinase receptors
- TLR, *see* Toll-like receptors
- TNF- α , 53, 221
- Tocopherol, 262
- Toll-like receptors, 59, 166, 198
- Transforming growth factor (TGF)- β , 161, 173, 202, 221
- receptor II, 51
- signaling, 49
- Transporters associated with antigen processing (TAP)-1 and TAP-2, 167
- Treg, *see* Regulatory T cells
- Tumor-associated macrophages, 171
- anti-tumor immunity inhibition and, 137
- cancer therapies and, 145–146
- hypoxia and, 133–134
- indolamine 2,3-dioxygenase (IDO) and, 146–147
- and MDSCs, 147–149
- NF- κ B, transcription factor, 138
- RNA signatures of, 144
- tumor cell invasiveness and metastasis, 134–136
- Tumor-derived factors, MDSCs expansion, recruitment and activation and, 161–162
- CSF-1, 163
- GM-CSF, 165–166
- IFN- γ , 167–169
- IL-6, 164
- IL-10, 166
- IL-13, 167
- PGEs, 169
- VEGF, 164–165
- Tumor-infiltrating lymphocytes, 74–75, 85–86, 220, 271
- signal transduction inhibition, by tumor, 78–80
- Tumor microenvironment, galectin-1 in, 237

- Tumor necrosis factor (TNF) receptor/ligand superfamily, 30
- Tumor stroma, antitumor immune response and, 281
 - chemotherapy and radiation, 288–289
 - eradication of established tumors and, 282–284
 - induced sensitization of, 284–288
- Tyro3 family, 201–203
- Tyrosinase, 8
- Tyrosine kinase receptors
 - c-kit* and imatinib mesylate, 203–205
 - Tyro 3 family receptors, 201–203
- Vascular endothelial growth factor (VEGF), 109, 111, 133–134, 161, 164–165, 171, 200, 225
- Virus envelope protein (env), 8
- v-myc* and *v-raf* oncogenes, 166
- ZAP70, 81–82